Accumulating studies have also confirmed that inhibiting the NF-κB signaling pathway can attenuate the symptoms of alcoholic liver injury and gouty arthritis by inhibiting the release of proinflammatory cytokines (Amen et al., 2020; Ouyang et al., 2021). Here, NFKB1 is linked to gout.